Non-Alcoholic Steatohepatitis (NASH) Clinical Trial
Official title:
Prospective Cohort Assessing The Prevalence And Progress Of Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) In Chinese Subjects
This is a 10-year, longitudinal, observational study of patients with NAFLD/NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, the biospecimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.
Status | Recruiting |
Enrollment | 20000 |
Est. completion date | September 30, 2027 |
Est. primary completion date | May 31, 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Males or females aged 18 and older; - Adults being managed or treated for NAFL or NASH; - Be able to communicate meaningfully with the Investigator and be legally competent to provide written informed consent. Exclusion Criteria: - Incompetent to understand and/or sign the informed consent; - Ethanol consumption exceeding more than 14 standard beverages per week for males and more than 7 standard beverages per week for female; - Causes for secondary hepatic fat accumulation such as significant alcohol consumption, medications, Wilson's disease, viral infections, starvation or parenteral nutrition, among others, and conditions associated with microvesicular steatosis - Diagnosis of liver cirrhosis and/or hepatocellular carcinoma; - Diagnosis of chronic inflammatory disease (i.e. inflammatory bowel disease, rheumatoid arthritis, inflammatory lung disease, severe infectious diseases), other than NAFL/NASH. |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Humanity and Health Medical Centre | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
Humanity and Health Research Centre |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of NAFL/NASH in Chinese | Determine the prevalence of NAFLD/NASH in military beneficiaries ages 18 or above. This will be determined by the % of subjects determined to have NAFLD/NASH in Chinese subjects. | up to 10 years | |
Secondary | Live imaging analysis | Transient elastography (FibroScan) and/or MR elastography will provide a measurement of liver stiffness. The liver stiffness metrics will be tabulated for each of the three time points and assessed for change. | up to 10 years | |
Secondary | Exploration, identification and validation of the circulating biomarkers for prediction and diagnosis of NAFL/NASH in Chinese | Cytokeratin-18 (CK-18), fibrosis-4 (FIB-4), leptin, adiponectin, TNF-alpha, PAI-1, IL-6, MCP-1, retinoids and other potential biomarkers will be determined and analysed. | up to 10 years | |
Secondary | Liver histology analysis | Liver histology (derived from central reading of liver biopsy at entry, standard of care biopsy done during screening or follow-up) will be examined and scored. | up to 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04481594 -
A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06151964 -
A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese
|
Phase 1/Phase 2 | |
Completed |
NCT04019561 -
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.
|
Phase 2 | |
Completed |
NCT01694849 -
Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
Completed |
NCT02653300 -
A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)
|
Phase 2 | |
Completed |
NCT03517540 -
Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
|
Phase 2 | |
Withdrawn |
NCT05050721 -
Natural History of Non Alcoholic Fatty Liver Disease and Predictors of Advanced Fibrosis
|
||
Active, not recruiting |
NCT04682600 -
The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF
|
N/A | |
Enrolling by invitation |
NCT01950884 -
Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis
|
Phase 4 | |
Completed |
NCT04483947 -
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
|
Phase 1 | |
Completed |
NCT02927314 -
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
|
Phase 2 | |
Active, not recruiting |
NCT02612662 -
A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects
|
Phase 1 | |
Recruiting |
NCT06168383 -
To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .
|
Phase 2 | |
Terminated |
NCT02605616 -
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 2 | |
Completed |
NCT02158351 -
Gut Microbiota and Modulation of Liver Damage in NAFLD
|
||
Recruiting |
NCT04820036 -
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
|
N/A | |
Recruiting |
NCT05553470 -
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
|
Phase 1 | |
Recruiting |
NCT04639414 -
Combined Active Treatment in Type 2 Diabetes With NASH
|
Phase 4 | |
Withdrawn |
NCT04607655 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT02654665 -
Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults
|
Phase 3 |